Retaane is MIA in Alcon’s quarterly PR, and this is the first time that’s happened in at least five years. Alcon may finally be acknowledging that, even if Retaane were somehow approvable for wet AMD, it probably wouldn’t be worth launching. (Retaane may yet have a place in dry AMD, but the ongoing studies in that indication won’t be done until the next decade.)